|
US3906092A
(en)
|
1971-11-26 |
1975-09-16 |
Merck & Co Inc |
Stimulation of antibody response
|
|
CA1335429C
(en)
|
1986-03-07 |
1995-05-02 |
Geoffrey L. Smith |
Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
|
|
US6162620A
(en)
|
1986-03-07 |
2000-12-19 |
Cogent Limited |
Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
|
|
US6207161B1
(en)
|
1986-07-16 |
2001-03-27 |
City Of Hope |
Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
|
|
ES2116269T3
(es)
|
1989-03-21 |
1998-07-16 |
Vical Inc |
Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
|
|
WO1993014778A1
(en)
|
1992-01-23 |
1993-08-05 |
Vical, Inc. |
Ex vivo gene transfer
|
|
IL112820A0
(en)
|
1994-03-07 |
1995-05-26 |
Merck & Co Inc |
Coordinate in vivo gene expression
|
|
WO1995026204A1
(en)
|
1994-03-25 |
1995-10-05 |
Isis Pharmaceuticals, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
CA2191362A1
(en)
|
1994-06-02 |
1995-12-14 |
Mark Selby |
Nucleic acid immunization using a virus-based infection/transfection system
|
|
US6448389B1
(en)
|
1996-04-23 |
2002-09-10 |
The Wistar Institute Of Anatomy And Biology |
Human cytomegalovirus DNA constructs and uses therefor
|
|
US6562345B1
(en)
|
1996-11-12 |
2003-05-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
US6074645A
(en)
|
1996-11-12 |
2000-06-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
US6183752B1
(en)
*
|
1997-02-05 |
2001-02-06 |
Pasteur Merieux Serums Et Vaccins |
Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
|
|
EP1021548A1
(en)
|
1997-10-07 |
2000-07-26 |
University Of Maryland Biotechnology Institute |
Method for introducing and expressing rna in animal cells
|
|
JP2002500010A
(ja)
|
1997-12-23 |
2002-01-08 |
カイロン コーポレイション |
ヒト遺伝子および遺伝子発現産物ｉ
|
|
DE19910044A1
(de)
|
1999-03-08 |
2000-09-14 |
Bodo Plachter |
Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
|
|
US7390780B2
(en)
|
1999-04-23 |
2008-06-24 |
Alza Corporation |
Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification
|
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
|
WO2001023002A1
(en)
|
1999-09-30 |
2001-04-05 |
National Jewish Medical And Research Center |
Method for inhibition of pathogenic microorganisms
|
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
|
US6835383B2
(en)
|
2000-03-23 |
2004-12-28 |
City Of Hope |
Protein kinase deficient, immunologically active CMVpp65 mutants
|
|
CN1254234C
(zh)
|
2000-06-09 |
2006-05-03 |
莱古伦公司 |
质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
|
|
US7204990B1
(en)
|
2000-11-28 |
2007-04-17 |
Medimmune Vaccines, Inc. |
Attenuation of cytomegalovirus virulence
|
|
ATE490267T1
(de)
|
2001-06-05 |
2010-12-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
WO2003059381A2
(en)
*
|
2002-01-18 |
2003-07-24 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
WO2004058166A2
(en)
|
2002-12-23 |
2004-07-15 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
|
US20040228842A1
(en)
|
2003-02-27 |
2004-11-18 |
Shan Lu |
Compositions and methods for cytomegalovirus treatment
|
|
ATE485056T1
(de)
*
|
2003-03-24 |
2010-11-15 |
Intercell Ag |
Verbesserte impfstoffe
|
|
WO2005009346A2
(en)
|
2003-06-24 |
2005-02-03 |
Mirus Corporation |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
|
DE602004021260D1
(de)
*
|
2003-07-11 |
2009-07-09 |
Alphavax Inc |
Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
EP1675614A2
(en)
|
2003-10-11 |
2006-07-05 |
Inex Pharmaceuticals Corp. |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
DE102004035227A1
(de)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
US7976845B2
(en)
|
2004-11-29 |
2011-07-12 |
The Council Of The Queensland Institute Of Medical Research |
Human cytomegalovirus immunotherapy
|
|
US9068969B2
(en)
|
2004-12-28 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Cell based methods and systems for the identification of RNA regulatory sequences and compounds that modulate their functions
|
|
WO2006095259A2
(en)
|
2005-03-11 |
2006-09-14 |
Novartis Ag |
Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
WO2007070705A2
(en)
|
2005-12-15 |
2007-06-21 |
The Trustees Of The University Of Pennsylvania |
Cationic lipid-mediated vectors
|
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
|
EP3031469B1
(en)
|
2006-06-07 |
2023-08-23 |
The Trustees Of Princeton University |
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
|
|
AU2007280690C1
(en)
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
EP2176408B9
(en)
|
2008-01-31 |
2015-11-11 |
Curevac GmbH |
NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
CA2728739C
(en)
*
|
2008-06-20 |
2017-07-11 |
Duke University |
Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
AU2015210364B2
(en)
|
2008-10-09 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
CN102231979B
(zh)
|
2008-10-16 |
2014-10-29 |
玛瑞纳生物技术有限公司 |
基因沉默治疗剂的脂质体有效递送方法和组合物
|
|
ES2646630T3
(es)
|
2008-11-07 |
2017-12-14 |
Massachusetts Institute Of Technology |
Lipidoides aminoalcohólicos y usos de los mismos
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
US8734853B2
(en)
|
2008-11-17 |
2014-05-27 |
University Of North Texas Health Science Center At Fort Worth |
HDL particles for delivery of nucleic acids
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
|
WO2010148085A1
(en)
|
2009-06-16 |
2010-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rna nanoparticles and methods of use
|
|
US20110300205A1
(en)
|
2009-07-06 |
2011-12-08 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
HUE042177T2
(hu)
|
2009-12-01 |
2019-06-28 |
Translate Bio Inc |
Szteroidszármazék mRNS szállítására humán genetikai betegségekben
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
SI2556150T1
(sl)
|
2010-04-06 |
2016-12-30 |
Vakzine Projekt Management Gmbh |
Virusni delec, sproščen po infekciji sesalskih celic s človeškim citomegalovirusom (HCMV), ki vsebuje fuzijski protein, in uporaba le-tega
|
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
CA2801523C
(en)
|
2010-07-30 |
2021-08-03 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
RS63890B1
(sr)
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
PT3970742T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
US20130164289A1
(en)
|
2010-09-09 |
2013-06-27 |
Virginia Commonwealth University |
Human cytomegalovirus vaccine
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
JP2013544504A
(ja)
*
|
2010-10-11 |
2013-12-19 |
ノバルティス アーゲー |
抗原送達プラットフォーム
|
|
JP6099573B2
(ja)
|
2011-01-31 |
2017-03-22 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012158736A1
(en)
|
2011-05-17 |
2012-11-22 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
PL3586861T3
(pl)
|
2011-06-08 |
2022-05-23 |
Translate Bio, Inc. |
Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
|
|
US8916696B2
(en)
|
2011-06-12 |
2014-12-23 |
City Of Hope |
Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
|
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
TWI570240B
(zh)
|
2011-09-09 |
2017-02-11 |
默沙東公司 |
作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
BR112014008694A2
(pt)
*
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
|
WO2013054199A2
(en)
|
2011-10-12 |
2013-04-18 |
Novartis Ag |
Cmv antigens and uses thereof
|
|
KR102451116B1
(ko)
|
2011-10-27 |
2022-10-06 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
|
|
ES2874233T3
(es)
|
2011-11-11 |
2021-11-04 |
Variation Biotechnologies Inc |
Composiciones y métodos para el tratamiento de citomegalovirus
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
WO2013090186A1
(en)
|
2011-12-14 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleic acids, and acute care uses thereof
|
|
US20140378538A1
(en)
|
2011-12-14 |
2014-12-25 |
Moderma Therapeutics, Inc. |
Methods of responding to a biothreat
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
JP2015510495A
(ja)
|
2011-12-21 |
2015-04-09 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
器官または器官移植片の生存可能性または寿命を延長する方法
|
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
|
EP4721752A2
(en)
|
2011-12-30 |
2026-04-08 |
Cellscript, Llc |
Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
US10322089B2
(en)
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US10245229B2
(en)
|
2012-06-08 |
2019-04-02 |
Translate Bio, Inc. |
Pulmonary delivery of mRNA to non-lung target cells
|
|
ES2753138T3
(es)
|
2012-07-06 |
2020-04-07 |
Glaxosmithkline Biologicals Sa |
Complejos de proteínas de citomegalovirus
|
|
DK2877580T3
(en)
*
|
2012-07-27 |
2019-04-23 |
Hope City |
VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
MX2015005505A
(es)
|
2012-10-30 |
2016-01-08 |
Redvax Gmbh |
Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
CA2890061A1
(en)
|
2012-12-04 |
2014-06-12 |
Merck Sharp & Dohme Corp. |
Conditional replicating viral vectors
|
|
US9687448B2
(en)
|
2012-12-07 |
2017-06-27 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid lipid particle formulations
|
|
EP4331620A3
(en)
|
2012-12-07 |
2024-12-04 |
Translate Bio, Inc. |
Lipidic nanoparticles for mrna delivery
|
|
WO2014093574A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
US20160184458A1
(en)
|
2013-03-14 |
2016-06-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
DK2970456T3
(da)
|
2013-03-14 |
2021-07-05 |
Translate Bio Inc |
Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
|
|
CA2906732C
(en)
|
2013-03-15 |
2023-08-08 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
EP3049092A4
(en)
|
2013-09-24 |
2017-09-06 |
Duke University |
Compositions, methods and kits for eliciting an immune response
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
WO2015052570A1
(en)
*
|
2013-10-07 |
2015-04-16 |
Medizinische Universität Wien |
Implant and method for improving coaptation of an atrioventricular valve
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
MX2016005238A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
|
|
CN115058452A
(zh)
|
2013-12-03 |
2022-09-16 |
霍欧奇帕生物科技有限公司 |
Cmv疫苗
|
|
AU2014362234B2
(en)
|
2013-12-11 |
2019-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
|
|
ES2895651T3
(es)
|
2013-12-19 |
2022-02-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
|
CA2927254C
(en)
*
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
WO2015110659A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
|
|
US20170143848A1
(en)
|
2014-03-24 |
2017-05-25 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for the treatment of ocular diseases
|
|
AU2015251221A1
(en)
|
2014-04-23 |
2016-10-27 |
CARIPLO, Fondazione |
Human cytomegalovirus vaccine compositions and method of producing the same
|
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
US20150322115A1
(en)
|
2014-05-08 |
2015-11-12 |
Redvax Gmbh |
Means and methods for treating cmv
|
|
WO2015181142A1
(en)
|
2014-05-27 |
2015-12-03 |
Glaxosmithkline Biologicals S.A. |
Cytomegalovirus complexes and uses thereof
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
BR112016030852A2
(pt)
|
2014-07-02 |
2018-01-16 |
Shire Human Genetic Therapies |
encapsulação de rna mensageiro
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ポリヌクレオチドの末端修飾
|
|
US10125092B2
(en)
|
2014-09-05 |
2018-11-13 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
EP3015475A1
(en)
|
2014-10-31 |
2016-05-04 |
Novartis AG |
Mammalian cells expressing cytomegalovirus antigens
|
|
EP3031822A1
(en)
|
2014-12-08 |
2016-06-15 |
Novartis AG |
Cytomegalovirus antigens
|
|
US20180000953A1
(en)
|
2015-01-21 |
2018-01-04 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
EP3048114A1
(en)
|
2015-01-22 |
2016-07-27 |
Novartis AG |
Cytomegalovirus antigens and uses thereof
|
|
EP3047856A1
(en)
|
2015-01-23 |
2016-07-27 |
Novartis AG |
Cmv antigens and uses thereof
|
|
JP6816031B2
(ja)
|
2015-02-10 |
2021-01-20 |
オレゴン ヘルス アンド サイエンス ユニバーシティ |
非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
|
|
US20180030417A1
(en)
|
2015-02-16 |
2018-02-01 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Method of altering expression of alternative viral glycoprotein complexes
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
KR20180004820A
(ko)
|
2015-05-15 |
2018-01-12 |
큐어백 아게 |
적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
LT3313829T
(lt)
|
2015-06-29 |
2024-08-12 |
Acuitas Therapeutics Inc. |
Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP4286012A3
(en)
|
2015-09-17 |
2024-05-29 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
EP3364981A4
(en)
*
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
WO2017070620A2
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
MX2018004917A
(es)
|
2015-10-22 |
2019-04-01 |
Modernatx Inc |
Vacuna de virus sincitial respiratorio.
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
AU2016342049B2
(en)
|
2015-10-22 |
2023-05-18 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
CA3002912A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
|
MA43568A
(fr)
|
2015-12-17 |
2018-11-14 |
Modernatx Inc |
Polynucléotides codant pour la méthylmalonyl-coa mutase
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
US11377656B2
(en)
|
2016-03-10 |
2022-07-05 |
Novartis Ag |
Chemically modified messenger RNA's
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
WO2017201352A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
MA45036A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
AU2017266932B2
(en)
|
2016-05-18 |
2023-04-20 |
Modernatx, Inc. |
Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
|
|
WO2017201347A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
MA45032A
(fr)
|
2016-05-18 |
2019-03-27 |
Fundacion Para La Investig Medica Aplicada |
Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
|
|
WO2017201317A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
|
|
KR20230074598A
(ko)
|
2016-05-18 |
2023-05-30 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
WO2017201348A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
US10967057B2
(en)
|
2016-06-02 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Zika viral antigen constructs
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
MA46584A
(fr)
*
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
BR112019008481A2
(pt)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
EP3532613A4
(en)
|
2016-10-26 |
2020-05-06 |
ModernaTX, Inc. |
METHOD AND COMPOSITIONS FOR RNA MAPPING
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
US11572389B2
(en)
|
2017-01-27 |
2023-02-07 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
|
|
WO2018144778A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Polynucleotide secondary structure
|
|
EP3576751A4
(en)
|
2017-02-01 |
2021-08-04 |
ModernaTX, Inc. |
RNA ANTI-CANCER VACCINES
|
|
JP2020514321A
(ja)
|
2017-02-01 |
2020-05-21 |
モデルナティーエックス， インコーポレイテッド |
活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
US20200368162A1
(en)
|
2017-02-24 |
2020-11-26 |
Modernatx, Inc. |
Nucleic Acid-Based Therapy of Muscular Dystrophies
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
SMT202300097T1
(it)
|
2017-03-15 |
2023-05-12 |
Modernatx Inc |
Composto e composizioni per il rilascio intracellulare di agenti terapeutici
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
MA50751A
(fr)
|
2017-08-18 |
2020-06-24 |
Modernatx Inc |
Vaccins à base d'arnm efficaces
|
|
WO2019036683A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
ANALYTICAL METHODS BY HPLC
|
|
ES2983060T3
(es)
|
2017-08-18 |
2024-10-21 |
Modernatx Inc |
Variantes de ARN polimerasa
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
EP3713601A4
(en)
|
2017-11-21 |
2022-03-09 |
Modernatx, Inc. |
VACCINES AGAINST EPSTEIN-BARR VIRUS
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
CN113365639A
(zh)
|
2018-06-27 |
2021-09-07 |
摩登纳特斯有限公司 |
个性化癌症疫苗表位选择
|
|
WO2020056370A1
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3118947A1
(en)
|
2018-11-07 |
2020-05-14 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
CN113795579A
(zh)
|
2019-02-20 |
2021-12-14 |
摩登纳特斯有限公司 |
用于共转录加帽的rna聚合酶变体
|
|
CA3132975A1
(en)
|
2019-03-11 |
2020-09-17 |
Modernatx, Inc. |
Fed-batch in vitro transcription process
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
AU2020283030A1
(en)
|
2019-05-31 |
2021-12-23 |
Modernatx, Inc. |
Expanded T cell assay
|
|
CN114269918A
(zh)
|
2019-08-14 |
2022-04-01 |
摩登纳特斯有限公司 |
用于纯化体外转录的下游产物的方法
|
|
CA3154082A1
(en)
|
2019-09-11 |
2021-03-18 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20220349006A1
(en)
|
2019-09-19 |
2022-11-03 |
Moderna TX, Inc. |
Cap guides and methods of use thereof for rna mapping
|
|
EP4088281A4
(en)
|
2020-01-10 |
2024-02-21 |
ModernaTX, Inc. |
VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
CN115103682A
(zh)
|
2020-01-30 |
2022-09-23 |
摩登纳特斯有限公司 |
呼吸道病毒免疫组合物
|
|
JP7438604B2
(ja)
|
2020-02-07 |
2024-02-27 |
モデルナティエックス インコーポレイテッド |
ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
US20230181481A1
(en)
|
2020-05-15 |
2023-06-15 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating covid-19
|
|
WO2021237084A1
(en)
|
2020-05-21 |
2021-11-25 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
|
WO2021247817A1
(en)
|
2020-06-05 |
2021-12-09 |
Modernatx, Inc. |
Bacterial strains for dna production
|